SENL-101 is under clinical development by Hebei Senlang Biotechnology and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Relapsed Acute Myeloid Leukemia have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SENL-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SENL-101 overview

SENL-101 is under development for the treatment of T-cell type non-Hodgkin lymphoma, refractory or relapsed T-cell acute lymphoblastic leukemia (T-ALL), relapsed or refractory acute myeloid leukemia, T-cell lymphoblastic lymphoma and relapsed or refractory CD7+ leukemia. It is administered through parenteral route. It comprises T-cells to express CD7 targeting chimeric antigen receptors (CAR).

Hebei Senlang Biotechnology overview

Hebei Senlang Biotechnology is a pharamaceutial and healthcare company which is involved in using bio technology for treatment of immune cells. The company is headquartered in Dongguan, Hebei, China.

For a complete picture of SENL-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.